Ember Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EMBT research report →
Price Chart
About the company
Ember Therapeutics, Inc. operates as a biopharmaceutical company currently in its clinical development phase. Its core mission involves exploring the therapeutic applications of bone morphogenetic protein-7 (BMP-7) to engineer regenerative treatments.
- CEO
- Joseph Hernandez
- IPO
- 2015
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on EMBT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $398
- P/E
- -0.02
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -11.53
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 10.25%
- ROIC
- 46.02%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-17,421
- Net Income
- $-23,242-42.3%
- EPS
- $-0.01-43.2%
- OCF Growth
- +26.0%
- FCF Growth
- +26.0%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.44
- RSI (14)
- 52
- Avg Volume
- 1.73K
No earnings-call transcripts are available for EMBT yet.
- Free Float
- 0.0%
- Shares Outstanding
- 3.98M
- Float Shares
- 0
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 11, 16 | Rudolf John C | buy | 5,986 |
| Feb 11, 16 | Rudolf John C | buy | 455 |
| Feb 10, 16 | Rudolf John C | buy | 500 |
| Feb 10, 16 | Rudolf John C | buy | 565 |
| Feb 5, 16 | Rudolf John C | buy | 231 |
| Feb 5, 16 | Rudolf John C | buy | 560 |
| Feb 4, 16 | Rudolf John C | buy | 355 |
| Feb 2, 16 | Rudolf John C | buy | 14 |
| Feb 1, 16 | Rudolf John C | buy | 999 |
| Feb 1, 16 | Rudolf John C | buy | 1,200 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our EMBT coverage
Recent articles, reports, and earnings notes.
No research on EMBT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EMBT report →